New drug aims to boost immune system against advanced cancers
NCT ID NCT04328844
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers like lung cancer, melanoma, and lymphoma. The main goal is to see if the drug is safe and tolerable, both alone and combined with other treatments. Researchers also check how the drug affects the body's immune response against tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN, United Kingdom
-
Humanitas Research Hospital
Rozzano, Milan, 20089, Italy
-
Medical Oncology and Immunotherapy Unit, University Hospital of Siena
Siena, 53100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep lung cancer from returning after surgery?
- E-Learning could sharpen Doctors' eye for skin cancer
- Can tracking a rare eye cancer pave the way for new treatments?
- Can a new drug tame advanced solid tumors?
- Can a simple blood test spot lymphoma earlier?
- Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?